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Purpose: Volumetric modulated arc therapy (VMAT) can deliver intensity modulated radiotherapy (IMRT) like dose
distributions in a short time; this allows the expansion of IMRT treatments to palliative situations like brain
metastases (BMs). VMAT can deliver whole brain radiotherapy (WBRT) with hippocampal avoidance and a
simultaneous integrated boost (SIB) to achieve stereotactic radiotherapy (SRT) for BMs. This study is an audit of our
experience in the treatment of brain metastases with VMAT in our institution.
Methods and materials: Metastases were volumetrically contoured on fused diagnostic gadolinium enhanced
T1 weighted MRI/planning CT images. Risk organs included hippocampus, optic nerve, optic chiasm, eye, and brain
stem. The hippocampi were contoured manually as one paired organ with assistance from a neuroradiologist.
WBRT and SIB were integrated into a single plan.
Results: Thirty patients with 73 BMs were treated between March 2010 and February 2012 with VMAT. Mean follow
up time was 3.5 months. For 26 patients, BMs arose from primary melanoma and for the remaining four patients
from non-small cell lung cancer (n= 2), primary breast cancer, and sarcoma. Mean age was 60 years. The male to
female ratio was 2:1. Five patients were treated without hippocampal avoidance (HA) intent. The median WBRT
dose was 31 Gy with a median SIB dose for BMs of 50 Gy, given over a median of 15 fractions. Mean values for BMs
were as follows: GTV = 6.9 cc, PTV = 13.3 cc, conformity index = 8.6, homogeneity index = 1.06. Mean and
maximum hippocampus dose was 20.4 Gy, and 32.4 Gy, respectively, in patients treated with HA intent. Mean
VMAT treatment time from beam on to beam off for one fraction was 3.43 minutes, which compared to WBRT time
of 1.3 minutes. Twenty out of 25 assessable lesions at the time of analysis were controlled. Treatment was well
tolerated; grade 4 toxicity was reported in one patient. The median overall survival was 9.40 months
Conclusions: VMAT for BMs is feasible, safe and associated with a similar survival times and toxicities to
conventional SRT+/−WBRT. The advantage of VMAT is that WBRT and SRT can be delivered at the same time on
one machine.
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Brain metastases (BMs) are common in metastatic mel-
anoma and are associated with a decrease in quality and
quantity of life [1-3]. Melanoma cerebral metastases
tend to be multiple [4,5], and the cause of death in most
patients is central nervous system disease rather than
extra- cranial systemic disease [4,6,7]. Steroid therapy,
neurosurgery, stereotactic radiotherapy techniques (SRT),
and Whole Brain Radiation Therapy (WBRT) with or
without SRT have been the standard of care [8]. Cur-
rently, patients having SRT and WBRT require two sep-
arate courses of radiotherapy and two different plans,
and usually on two separate machines or even perhaps
separate centres. Conventional SRT can consume sig-
nificant linear accelerator time. WBRT has been associ-
ated with neurocognitive sequelae [9-12]. The organ at
risk is thought to be the limbic system especially the
hippocampus [13,14].
Volumetric modulated arc therapy (VMAT) can de-
liver conformal dose distributions like those delivered
with intensity modulated radiotherapy (IMRT) accur-
ately, but the delivery times are much faster than con-
ventional IMRT. The recent introduction of VMAT has
therefore allowed the expansion of conformal tech-
niques to more cases including palliative scenarios [15].
VMAT has enabled WBRT with hippocampal avoidance
(WBRTHA), with simultaneous Integrated boost (SIB)
to regions of macroscopic tumour, all within the one
radiotherapy course. As both the WBRT and SIB doses
are delivered simultaneously and within the same plan,
there are advantages in terms of better dosimetry, radio-
biological advantage and quality assurance compared to
sequential WBRT and radiosurgery (SRS) boosts, which
are delivered in separate courses at different times,
often on different machines [16,17].
Currently the Radiation Therapy Oncology Group
(RTOG) is investigating whether WBRTHA preserves
neurocognitive function (NCF) in patients with BMs
using IMRT techniques that include VMAT. In order to
fulfil the credentialing and attain in-house practice for
this trial, we planned and treated patients with BMs pre-
dominantly from melanoma. This is the first reported
Australian experience of this technique with patients
treated with WBRT with either hippocampal avoidance
(HA), SIB, or both.
Methods and materials
Patients treated with this technique were analysed retro-
spectively after approval by Sydney south west area health
service (SSWAHS) Ethics Review Committee. No formal
testing of hippocampal quality of life was performed either
before or after treatment in these patients. Patients were
treated with a Varian 21IX machine (RapidArc, Varian
medical systems] using two complementary arcs. Planningsoftware was Eclipse radiotherapy treatment planning sys-
tem, version 8.6.07W™ (Varian Medical Systems Inc.). A
planning target volume (PTV) for the whole brain was de-
rived from auto-segmentation of the brain on the CT scan,
with the addition of a 2 mm symmetrical margin. For pa-
tients treated with SIB to individual metastases, the gross
tumour volume (GTV) were volumetrically contoured on
fused diagnostic gadolinium enhanced T1 weighted MRI/
planning CT images. GTV for each target metastasis was
identified as the gadolinium -enhancing lesion on the T1-
weighted MRI. PTV for each metastasis was outlined
using a computer-automated 2 mm 3D margin expansion
of the GTV for each metastasis. Organs at risk included
hippocampus, optic nerve; optic chiasm, eye, and brain
stem were outlined.
Method of hippocampal avoidance
Both hippocami were defined as one paired organ. The
hippocampi were contoured manually with assistance
from a neuroradiologist, with reference to the on-line
RTOG contouring atlas specified on (www.rtog.org/
corelab/contouringatlases/hippocampalsparing.aspx). As
per ongoing RTOG 0933 protocol, HA regions were
generated by three-dimensionally expanding the hip-
pocampal contours by 5 mm. The HA regions were
subtracted from the WBRT PTV. WBRT and SIB were
integrated into a single plan. Both WBRT and SIB doses
were prescribed at 100%, according to the ICRU criteria
[18]. The minimally accepted doses to the WBRT PTV
and the SIB PTV were 95% of the prescription dose.
There was no maximum dose limit for the brain metas-
tasis, although typically this was confined to 110% of the
prescribed dose. All dose calculations were performed
with Eclipse v. 8.6.07 using the AAA calculation model
with a calculation grid of 2.5 mm.
VMAT quality assurance
The quality of the VMAT plans was assessed according
to the following measures:
Dose homogeneity using MDPD, defined as the max-
imum dose (MD) divided by the prescription dose (PD).
This dosimetric parameter for homogeneity was defined
by the RTOG in SRS Quality Assurance (QA) guideline
[19]. We used the same criteria from the RTOG guide-
lines, that is, MDPD should be <1.25. An MDPD be-
tween 1.25 and 1.40 constitutes a minor variation and
an MDPD >1.40 is a major deviation.
Dose conformity for the target metastases was quanti-
fied using PITV, defined as the prescription isodose vol-
ume (PI) divided by the target volume (TV). In the
RTOG QA guidelines [19], PITV should be kept as close
to 1.0 as possible while maintaining target coverage and
target homogeneity criteria. A PITV between 1.0 and
2.0 is optimal. A PITV between 2.0 and 2.5 is a minor
Table 2 Lesion location






Brain stem 3 4%
Other* 10 14%
Total 73 100%
Other*: Ventricular, thalamus, parieto-occipital, orbital, centrum, pons,
midbrain, pre-central gyrus, inter-hemispheric fissure.
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department quality assurance (QA) was performed by
Physics for each plan through a method of film dosim-
etry. For QA for each plan, film was placed in a cylin-
drical phantom and irradiated. Planned arcs were copied
onto a CT data set of the cylindrical phantom, calcu-
lated, and a dose plane equivalent to the film’s area was
exported. Films were scanned and compared to the
exported planer dose from the planning system. Using
an in-house film dosimetry analysis program, plans were
judged suitable if the plan versus film analysis passed a
3mm/ 3% gamma-value analysis test [20].
Results
Thirty patients with 73 brain metastases were treated
between March 2010 and February 2012 with VMAT.
Patient demographics are summarized in Table 1. The
median patient age at diagnosis of the treated brain
lesions was 60 years (range: 26–84 years). The male to
female ratio was 2:1. For 26 patients, BMs arose from
primary melanoma and for the remaining four patients
from non-small cell lung cancer (n= 2), primary breast
cancer, and sarcoma. The median number of lesions per
patient at the time of radiotherapy treatment was 2
(range: 1–8).
The anatomical locations of the brain lesions are sum-
marized in Table 2. The majority of the lesions were
located in the frontal lobe (33%). The median follow-up
after completion of radiotherapy for 22 patients was 3.5
months (range: 0.03–16.5 months); seven patients were
lost to follow-up, and one patient had treatment plan-
ning only before deteriorating from extracranial disease.
At last-follow-up of the cohort, 11 patients were de-
ceased, including the patient who had only treatment
planning.
Priority was placed on giving sufficient SIB dose, and
HA was not attempted in these cases where lesionsTable 1 Patient characteristics
Value N
Patient Sex Male 20
Female 10








others*: lung (2), breast (1) and sarcoma (1), WBRTHA*: whole brain
radiotherapy with Hippocampal avoidance, SIB*: simultaneous
integrated boost.where close to the hippocampi, usually within 10mm.
Twenty out of twenty two of the patients treated with
WBRT had WBRTHA. The mean hippocampal dose
for these patients ranged from 4.3 to 18.0 Gy and the
maximum dose ranged from 8.4 to 32.2 Gy. For patients
not receiving HA (n=10), the mean hippocampal dose
ranged from 25.8 to 51.6 Gy and the maximum dose
ranged from 24.3 to 56.5 Gy (Figure 1). The maximum
and mean hippocampal dose were each significantly in-
creased for patients not receiving HA (p<0.001, Mann–
Whitney U). Figure 2 shows dose distribution in the WB
and BMs with HA on an axial planning CT slice from a
representative patient.
Twenty-two patients received WBRT with SIB to
metastatic lesions, one patient received WBRTHA only,
and seven patients received high dose fractionated
VMAT only as listed in Table 3. WBRT was conducted
for 23 patients with a median dose of 30 Gy (range
28.6–37.5 Gy). The median dose to BMs was 50 Gy
(range: 20–70.8 Gy), delivered in a median of 15 frac-
tions. Median beam-on treatment time recorded for 28
patients was 3.43 minutes (range: 1.2–6.3 minutes).
As shown in Table 3, MDPD was in the optimal range
(<1.25) for all lesions. The PITV was in the optimal range
for 20% of lesions, with minor and major deviations in
9% and 59%, respectively, in measurable lesions (n=64).
Eighty-two percent of lesions having major deviations
from optimal PITV (n=38) had GTV less than 1 cc.
Treatment outcomes
Tumour control was able to be assessed for 27 lesions
(37%) in 15 of the 29 patients who had SIB (excluding
the 1 patient who had adjuvant WBRTHA) at the time
of the analysis. Twenty two lesions (81%) were con-
trolled (any response or stable disease) for 13 patients,
and five lesions (29%) were uncontrolled in four patients
at a median follow up of 3.5 months. Three patients
showed distant intracranial failure yet with controlled
treated BMs. For the controlled (22) versus uncontrolled



























Hippocampal Sparing No Hippocampal Sparing
p<0.001
Figure 1 Maximum hippocampal dose for patients having HA versus no HA p<0.001.
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dose, PITV. Four patients (7 lesions) died before assess-
ment of tumour control was done. For the remaining 39
lesions (13 patients), it was not possible to assess treated
disease control at data collection time in this retrospect-
ive cohort.
Overall survival from the end of radiotherapy for
22 patients was a median of 9.40 months (95% CI:
1.95–16.85). HA, number of lesions, patient age and
sex, WBRT dose and SIB dose did not significantly
influence overall survival.
Acute toxicity was minimal, and was predominantly
alopecia, headache and vomiting. Grade I was recorded
for 5 patients, grade I/II for 2 patients, and grade II forFigure 2 VMAT dose colour wash for WB_ SIB_HA on planning
CT of a representative patient. Dose to metastasis was
escalated (red, 63 Gy), WB at lower dose (green, 32.5 Gy), with
HA (contour yellow).3 patients. One patient experienced grade IV late tox-
icity. This was histologically proven brain necrosis
without tumour recurrence in two melanoma lesions
following ipiluminab, a phenomenon which has been
reported in other studies [21].
Discussion
The main goal of palliation is to improve quality of life
and perhaps increase quantity of life. Important quality
of life endpoints for patients suffering with metastatic
melanoma to the brain include control of neurological
symptom and with as less impact on NCF as possible.
VMAT with WBRTHA and SIB may deliver all these in
one radiotherapy course. This study reports the experi-
ence of using VMAT to streamline WBRT with hippo-
campal sparing and SIB in the Australian context.
Our study compromised 30 patients with 73 brain le-
sions. The 26 patients with 54 lesions were from primary
melanoma. For 20 patients treated with HA, the mean
hippocampal dose ranged from 4.3 to 18.0 Gy and the
maximum dose ranged from 8.4 to 32.2 Gy, compared
to mean hippocampal dose ranged from 25.8 to 51.6 Gy
and the maximum dose ranged from 24.3 to 56.5 Gy for
patients not receiving HA (n=10). The median treatment
time per fraction, recorded for 28 patients, was 3.43 mi-
nutes which compared to WBRT time of 1.3 minutes.
This compares well with Hsu et al. [22]. This treatment
therefore saves machine time when compared even to
other conformal techniques, as has been found in other
tumour sites [15]. More importantly, VMAT minimises
time spent at hospital with the single planning session
and short daily fraction time.
For the patients treated with SIB, our VMAT plans
met the RTOG SRS guidelines. MDPD was in the opti-
mal range (<1.25) for all lesions, while the PITV was in
the optimal range for 20% of lesions, with minor and
major deviations in 9% and 59% respectively in measur-
able lesions (n=64). This high percentage of major PITV
deviation might explained by the fact that 82% of lesions
(n=38) having major deviations from optimal PITV had
GTV less than 1 cc. PITV does not appear to be import-
ant for lesions < 1 cc [23].
Table 3 Planning summary for 73 lesions (30 patients)
Specification Abbrev. Units No* Median Mean Minimum Maximum
Whole-brain radiotherapy (Gy)* WBRT pts* 23 30.0 30.6 28.6 37.5
Fraction Frx les 73 10.0 11.8 5.0 15.0
Dose to hippocampus with HA ) (Gy) HA pt 20 21.9 20.4 8.4 32.2
without HA (Gy) - pts 10 29.0 41.1 24.3 56.5
Simultaneous integrated boost (Gy) SIB pts 29 45.0 44.8 20.0 70.8
Gross target volume (cc)* GTV les* 71 0.6 6.9 0.02 291.3
Planning target volume (cc) PTV les 67 3.3 13.3 0.4 344.0
Prescription isodose volume (cc) PIV les 64 2.4 12.6 0.1 389.0
Maximum dose (Gy)* MD les 73 45.6 47.1 22.0 72.0
Prescription dose (Gy) PD les 71 45.0 44.8 20.0 70.8
Conformity index PITV les 64 3.2 8.6 0.2 70.0
Homogeneity MDPD les 71 1.06 1.06 1.01 1.10
Beam time (min) BT les 68 3.4 3.6 1.2 6.3
No*: number, (Gy)*: Graypts*: patient, les*: lesion, (cc)*: cubic centimetre, (Gy)*: Gray.
Awad et al. Radiation Oncology 2013, 8:62 Page 5 of 6
http://www.ro-journal.com/content/8/1/62In our study, twenty two of twenty-seven (81%) assess-
able lesions in 22 melanoma patients were controlled at a
median time of 3.5 months after completion of radiother-
apy. This compares well with the reported results of SRS
in melanoma BMs of other studies [24-26]. There was dis-
tant intracranial failure in 2 patients, yet with controlled
metastases which is comparable to the control seen in
other studies of WBRT in melanoma [27]. Our results
show that VMAT can deliver comparable results to the
current conventional treatments of SRS with or without
WBRT. Shehata et al. [28] reported local control rate
of 97% versus 87 %,for 468 BMs treated SRS ± WBRT,
respectively, including melanoma patients. Other series of
Gamma Knife SRS alone in melanoma patients with BMs
showed a local control rate of 83% [29].
Acute toxicity overall was minimal, only one patient
experienced grade IV late toxicity. These results are
similar to the findings of Weber et al. [30] reported the
achievement of delivery of WB VMAT 30 Gy and a SIB
to the BMs 40 Gy in 10 fractions with no significant tox-
icity and stable Qol during treatment. Formal pre and
post treatment quality of life (Qol) assessment was be-
yond the scope of this retrospective analysis.
We report an overall survival of 9.4 months. In a multi-
institutional retrospective review [31] of almost 4000
patients with newly diagnosed BMs, the median survival
was 6.74 months for 481 metastatic melanoma patients
treated with SRS ± WBRT. A pooled analysis [32] of 120
patients treated with VMAT SIB for dose-escalation of
oligometastatic disease of the brain, reported a median
overall survival of 5.9 months after a median follow up of
4.7 months for the entire group. There were no cases of
patient death attributable to toxicity from the SIB brain
radiotherapy. VMAT is at least comparable to current
treatment techniques in terms of overall survival.This report shows that VMAT can deliver effective
and efficient WBRT with either HA, SIB, or both in pa-
tients with BMs. The ability to do this is becoming more
important as melanoma patients are living longer with
new targeted therapies [33] that can even cross the
blood brain barrier and have efficacy in the brain. The
resulting increase in progression free survival means
avoiding WBRT toxicity is even more important.
Conclusion
This is the first reported Australian experience of pa-
tients treated with WBRT with either HA, SIB, or both
via VMAT. This treatment is feasible and tolerable.
VMAT was able to deliver SRS quality dose distributions
to individual metastases while adequately delivering
WBRT and conformably sparing the hippocampus. The
mean time to deliver this treatment with VMAT was less
than 3.43 min, making this treatment approach attract-
ive from the practical standpoint. There was no add-
itional toxicity and survival was similar to conventional
treatments.
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